Johnson & Johnson today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human ...
New research reveals how complex interactions between genetic variants can explain different outcomes in disorders like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback